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Abstract Mitochondrial diseases are characterised by clini-
cal, molecular and functional heterogeneity, reflecting their bi-
genomic control. The nuclear geneGFM2 encodes mtEFG2, a
protein with an essential role during the termination stage of
mitochondrial translation. We present here two unrelated pa-
tients harbouring different and previously unreported com-
pound heterozygous (c.569G>A, p.(Arg190Gln); c.636delA,
p.(Glu213Argfs*3)) and homozygous (c.275A>C, p.(Tyr92Ser))
recessive variants in GFM2 identified by whole exome se-
quencing (WES) together with histochemical and biochemical
findings to support the diagnoses of pathological GFM2 var-
iants in each case. Both patients presented similarly in early
childhood with global developmental delay, raised CSF lac-
tate and abnormalities on cranial MRI. Sanger sequencing of
familial samples confirmed the segregation of bi-allelicGFM2
variants with disease, while investigations into steady-state
mitochondrial protein levels revealed respiratory chain sub-
unit defects and loss of mtEFG2 protein in muscle. These data
demonstrate the effects of defective mtEFG2 function, caused
by previously unreported variants, confirming pathogenicity
and expanding the clinical phenotypes associated with GFM2
variants.
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Introduction
Mitochondrial disorders are a genetically and clinically het-
erogeneous group of diseases which can arise due to defects in
the oxidative phosphorylation (OXPHOS) system. The
OXPHOS system comprises five multi-subunit protein com-
plexes—the electron transport chain (complexes I–IV) and
ATP synthase (complex V)—which function together to gen-
erate cellular energy in the form of ATP.Mitochondria possess
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their own circular, double-stranded 16,569 bp genome,
encoding 22 transfer RNAs (tRNAs), 2 ribosomal RNAs
(rRNAs) and 13 polypeptides [1]. All OXPHOS components,
with the exception of complex II, are under bi-genomic con-
trol and as such are the product of both nuclear DNA and
mitochondrial DNA (mtDNA)-encoded proteins [2]. Nuclear
genes also encode the proteins responsible for mtDNA main-
tenance, mitochondrial transcription and translation and all
other mitochondrial processes. As a consequence, mutations
in either mitochondrial or nuclear genes may compromise
ATP synthesis and cause mitochondrial disease. Extensive
clinical and genetic heterogeneity makes the identification,
characterisation and diagnosis of mitochondrial disease chal-
lenging, because clinical features often overlap with other
neurological or systemic diseases. The advent of next-
generation sequencing, specifically whole exome sequencing
(WES), has improved the identification of disease-causing
pathogenic variants in many different genes resulting in a
much greater diagnostic yield than previous candidate gene
screening approaches [3].
Mutations in genes involved in the translation of mtDNA
are well-documented causes of mitochondrial disease [4, 5].
These genetic variants characteristically lead to combined
OXPHOS deficiencies. The spectrum of resulting clinical phe-
notypes is broad, often manifesting as multi-system disease
with the heart, skeletal muscle, brain and liver commonly af-
fected [6]. The translational machinery within mitochondria is
distinct to that of the cytosol and has several features which are
reminiscent of the system employed in prokaryotic protein
synthesis. This is reflective of the evolutionary origins of mi-
tochondria as an endosymbiont α-proteobacterium [7].
Mitochondria possess their ownmitoribosome which is a com-
bination of 12S and 16S rRNAs, encoded within themitochon-
drial genome, and at least 80 nuclear genes encode the proteins
that form the large and small mitoribosomal subunits [8].
Pathogenic variants have been described in several of the
mitoribosomal subunits [9–11]. Mitochondrial translation de-
fects can also arise due to mutations in the mitochondrial
tRNAs and in the mitochondrial protein translation factors
[12]. Mitochondrial amino-acyl tRNA synthetases (mt-
aaRSs) are a group of enzymes with an essential role within
mitochondrial protein synthesis and are associated with a con-
tinuously expanding number of mitochondrial disease presen-
tations. There are 19 mt-aaRSs, which utilise ATP to specifi-
cally catalyse the attachment of amino acids to their cognate
tRNA [13]. Mitochondrial diseases resulting from mutations
in genes encoding all 19 of the mt-aaRSs have now been
described in the literature, with the most recently identified
being WARS2 [14].
The human genes GFM1 and GFM2 encode the proteins
mtEFG1 and mtEFG2, respectively, both of which are homo-
logs of the highly conserved bacterial translation elongation
factor G (EF-G) [15]. EF-G functions at multiple stages within
prokaryotic protein synthesis, with roles in the translocation of
the ribosome during elongation and ribosome recycling upon
termination or stalling of translation [16]. In human mitochon-
dria, the dual roles of prokaryotic EF-G are carried out by the
two distinct human homologs. Human mtEFG1 acts as an
elongation factor with mitoribosome translocation activity,
while mtEFG2 functions at the termination step of translation
to disassemble the mitoribosome and allow subsequent cycles
of mitochondrial protein synthesis [17].
Seventeen mitochondrial disease patients with GFM1 mu-
tations across 13 families have been described in the literature
so far. Earlier cases were associated with very severe systemic
disease with early or neonatal onset, resulting in death within
the first 2 years of life. Some clinical features, such as micro-
cephaly, liver disease and encephalopathy, were common to
multiple cases. However, more recent publications have de-
scribed a new, milder, disease progression associated with
GFM1mutations, with survival at 6 and 7 years of age [18, 19].
Two families with gene defects in GFM2, identified
through whole exome sequencing, have previously been de-
scribed in the literature associated with Leigh syndrome, mi-
crocephaly, simplified brain gyral pattern and insulin-
dependent diabetes [20, 21]. Here we present two unrelated
patients with previously unreported variants in GFM2,
documenting OXPHOS deficiencies in different tissues and
expanding the clinical phenotypes associated with GFM2-re-
lated mitochondrial disease.
Patients and methods
All studies were completed according to local Ethical
Approval of the Institutional Review Boards of Newcastle
University (the National Research Ethics Service Committee
North East—Newcastle & North Tyneside 1) and of the
Technische Universität München. In agreement with the
Declaration of Helsinki, all individuals or their guardians pro-
vided written informed consent before undergoing evaluation
and genetic testing.
Patient 1
Patient 1, an 11-year-old male, is the first child of healthy non-
consanguineous parents and has a healthy younger brother.
Pregnancy was complicated by intrauterine growth restriction
and he was born at term, in good condition, by normal vaginal
deliveryweighing 2.0 kg. He had asymptomatic hypoglycaemia
in the neonatal period and mild jaundice and was tube fed ini-
tially. He subsequently had a urinary tract infection and required
orchidopexy for an undescended right testis.
Developmental delay was first noted at 2.5 years in relation
to language and communication skills; he had acquired his
first words at 12–18 months, but did not put words together
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until aged 3 years. From 5 years onwards, he has become
increasingly dysarthric. He has used a knife and fork from
3 years of age but has never been able to write. He started
walking at 14 months and could run at 4 years but he subse-
quently developed a dystonic posture of his right foot and
spasticity in both legs, leading to toe walking and loss of
ambulation at 8 years; he currently mobilises by crawling.
He has been continent since 2 years of age and continues to
make slow academic progress. He has a normal head circum-
ference, normal vision and hearing and no involuntary move-
ments or seizures.
Cranial MRI showed symmetrical bilateral high signal on
T2-weighted images in the caudate, putamen and cerebellar
dentate nucleus. There were also abnormalities in the corpus
callosum and the subcortical white matter of the cerebral and,
particularly, the cerebellar hemispheres, with further abnormal
areas in the deep white matter (Fig. 1a, b). CSF lactate was
elevated on two occasions at 3.2 and 3.4 mmol/L (normal
range, 0.7–2.1 mmol/L). Sequencing of the mitochondrial ge-
nome and the NFU1 gene were both normal.
Patient 2
Patient 2, a 7-year-old female, is the second child of consan-
guineous parents originating from Syria. Born following an
uneventful pregnancy at full term, development was unre-
markable in the first 2 years of life. At the age of 2 years and
2 months, involuntary movements of the left hand were re-
ported and within a fewmonths, these had extended to involve
all four limbs. Muscle strength and mass deteriorated and she
lost the ability to walk at 4 years, to sit at 5 years and subse-
quently lost the ability to speak. At the age of 6 years, she
presented with her first seizure and has subsequently devel-
oped a severe epilepsy disorder. Clinical assessment reveals
severe global developmental delay, myopathic facies with an
open mouth appearance and drooling, severe axial hypotonia
with hypertonic limbs and dystonic involuntary movements.
Communication was restricted to phonetic reading.
Lactate was repeatedly elevated in both serum (up to
4.1 mmol/L) and CSF (up to 3.1 mmol/L). Cranial MRI
showed diffuse hyperintensities on T2-weighted imaging of
Fig. 1 Cranial MRI, histochemical and biochemical investigations. MRI
of Patient 1 showing bilateral T2 hyperintensities involving supratentorial
white matter (yellow arrows), head of caudate nucleus (white arrows),
putamen and genu and splenium of the corpus callosum (a) characterised
by low T1 signal suggesting irreversible tissue damage (b). MRI of
Patient 2 showing extensive T2 hyperintensities associated with volume
loss involving bilateral periventricular and central white matter (d, e,
yellow arrows) and defects involving both putamina and the head of
caudate nucleus on the right (c, d, f, white arrows). Right (R) and left
(L) are indicated. (g) Haematoxylin and eosin stain shows normal skeletal
muscle morphology. Succinate dehydrogenase (SDH) (h), cytochrome c
oxidase (COX) (i) and COX-SDH histochemistry (j) reveal a generalised
and widespread COX deficiency. Respiratory chain enzyme activity
measurements in skeletal muscle (k) and fibroblasts (l) demonstrate a
severe complex IV defect in skeletal muscle and a mild complex I and
IV defect in Patient 1 fibroblast cells compared to age-matched controls
(red: controls, blue: patient 1)
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the periventricular and central white matter with associated
volume loss and atrophy of corpus callosum as well as T2
hyperintense defects of bilateral putamen and head of caudate
nucleus (Fig. 1c–f). EEG revealed multifocal seizure activity.
Histopathology and biochemistry
A diagnostic skeletal muscle biopsy was obtained from
Patient 1 with informed consent; histological and histochem-
ical investigations were carried out following standard proce-
dures. The biochemical assessment of respiratory chain en-
zyme activities was undertaken as previously described in a
skeletal muscle homogenate [22].
Molecular genetic studies
WES was carried out for both patients to identify candidate
pathogenic variants. Methodologies and variant filtering pipe-
lines were carried out as previously described in [23, 24] for
Patient 1 and Patient 2, respectively. Variants with a minor
allele frequency (MAF) ≥ 0.01 (1%) on external sequencing
databases such as the Genome Aggregation Database
(gnomAD), and in-house control data sets, were excluded
from the variant pool. Autosomal recessive variants (either
compound heterozygous or homozygous) in genes known to
encode proteins with mitochondrial function were then
prioritised for further investigation.
Sanger sequencing of amplified gene products was carried
out in accordance with BigDye® Terminator v3.1 Cycle
Sequencing Kit manufacturing protocol. Sequencing primers
for each variant were designed, using Primer3 (http://primer3.
ut.ee), and sequences are available on request.
Sequence analysis and in silico pathogenicity prediction
Sequence data was viewed and analysed using FinchTV.
Variants are named according to transcript variant 1 of
GFM2 (GenBank accession number: NM_032380.4).
Multiple sequence alignments were carried out using
SeaView. Four freely available web-based programmes,
Align GVGD (http://agvgd.iarc.fr/agvgd_input.php), SIFT
(http://sift.jcvi.org), PolyPhen (http://genetics.bwh.harvard.
edu/pph2/) and Combined Annotation Dependent Depletion
(CADD) (http://cadd.gs.washington.edu/home), were used to
predict the pathogenicity of the missense amino acid changes
present in each patient through the analysis of Grantham
differences and sequence homology.
Cell culture
Primary fibroblast cell lines for both patients and paediatric
controls were incubated at 37 °C in a humidified 5% CO2
atmosphere and grown in 75-cm2 flasks of 12 mL Gibco®
MEM (minimum essential medium) containing 1 mM pyru-
vate, 2 mM L-glutamine and 4500 mg/L glucose, and supple-
mented with 10% FCS, 1× non-essential amino acids, 1×
penicillin/streptomycin and 50 μg/mL uridine.
Sample preparation, SDS-PAGE and Western blot
analysis
Fibroblast cell pellets were re-suspended in lysate buffer
(50 mM Tris/HCl pH 7.4, 130 mM NaCl, 2 mM MgCl2,
1 mM PMSF, 1% Nonidet P-40, 1× EDTA-free protease in-
hibitor), vortexed for 30 s and centrifuged at 1000g for 2 min,
retaining the supernatant. Skeletal muscle (10-15 mg) was
frozen in liquid nitrogen, then powdered and suspended in
1 mL RIPA buffer (1% IGEPAL, 0.5% sodium deoxycholate,
0.1% SDS, 1.5% Triton X-100, 10 mM beta mercaptoethanol,
protease inhibitor (Pierce) and 1 mM PMSF in PBS). The
muscle homogenate was then vortexed, incubated on ice for
45 min and subjected to 2 × 5-s homogenisations in a polytron
tissue homogeniser. The final muscle lysates were prepared by
centrifugation at 14,000g for 10 min at 4 °C, retaining the
supernatant. Lysed fibroblast and muscle samples were incu-
bated with dissociation buffer, containing 6.25 mM Tris/HCl
pH 6.8, 2% SDS, 10% glycerol, 0.01% bromophenol blue and
100 mM DTT, for 20 min at 37° C.
All protein lysates were electrophoresed through 12%
polyacrylamide resolving gels, cast, run and transferred on
Bio-Rad Mini-Protean® Tetra Cell systems, at 200 V. Target
proteins were interrogated by incubation overnight with anti-
bodies at 4 °C and the resulting signals were visualised with
ECL-prime (GE Healthcare) using Image Lab software on a
BioRad Chemidoc MP. Antibodies used were the following:
SDHA (ab14715; Abcam), ATP5A (ab110273; Abcam),
ATP5B (ab14730; Abcam), UQCRC2 (ab14745; Abcam),
MT-CYB (55090-1-AP; Proteintech Europe), MT-COI
(ab14705; Abcam), MT-COII (ab110258; Abcam),
NDUFB8 (ab110242; Abcam) and GFM2 (ab74874; Abcam).
[35S] metabolic labelling
Assessment of de novo mitochondrial protein synthesis was
carried out in patient and control fibroblasts grown to a
confluency of 80%. Cells were washed three times for
10 min in methionine/cysteine-free media (Sigma, D0422)
before adding 10% dialysed FCS (Sigma F0392) and
100 μg/mL emetine dihydrochloride to inhibit cytosolic trans-
lation. 20 μl of [35S]-methionine/cysteine mix (Perkin-Elmer
Easy Tag Express protein labelling mix, NEG-772, 73% L-
met, 22% L-cys) was added to each flask and cells were incu-
bated at 37 °C for 1 h. Cells were then washed in standard
growth media containing methionine and harvested in PBS +
1 mM EDTA, pelleted at 200g for 4 min and resuspended in
PBS + 1 mM PMSF and 1× EDTA-free protease inhibitor
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before being subjected to 15% SDS-PAGE as before. The gel
was stained with Coomassie brilliant blue, fixed overnight
(30% methanol, 10% acetic acid, 3% glycerol) and vacuum-
dried prior to exposure using a PhosphorImage screen. Signal
was detected using the Typhoon FLA9500 Phosphorimager
and ImageQuant software (GE Healthcare) and mtDNA-
encoded proteins were assigned to corresponding bands with
reference to Chomyn et al. [25].
Results
Histopathological and biochemical studies
The muscle morphology of Patient 1 revealed no marked
structural abnormalities visible upon staining with H&E
(Fig. 1g). Oxidative enzyme histochemistry showed intense
succinate dehydrogenase (SDH) activity (Fig. 1h) and a gen-
eralised decrease in cytochrome c oxidase (COX) activity
across the biopsy (Fig. 1i). Sequential COX-SDH histochem-
istry confirmed widespread COX deficiency in the presence of
normal SDH activity (Fig. 1j). The assessment of respiratory
chain enzyme activities in muscle from Patient 1 revealed
impairment of complex IV activity, while the activities of
complexes I and II were both within normal limits (Fig. 1k).
Interestingly, the fibroblast cells from this patient appeared to
express a mild combined OXPHOS defect involving both
complexes I and IV, albeit with residual enzyme activities of
~ 60% of normal (Fig. 1l).
Variant identification, confirmation and segregation
studies
WES of Patient 1 identified compound heterozygous vari-
ants in the GFM2 gene, a c.569G>A single nucleotide sub-
stitution in exon 8 resulting in an arginine to glutamine
missense change at residue 190 (p.(Arg190Gln)) and a
c.636delA single nucleotide deletion in exon 9 producing
a frameshift mutation and premature termination codon
(p.(Glu213Argfs*3)) that can be classified as pathogenic
without further work (Fig. 2a). WES of Patient 2 revealed
a homozygous c.275A>C variant in exon 5 of GFM2, pre-
dicted to cause a tyrosine to serine missense change at
residue 92 (p.(Tyr92Ser)) (Fig. 2b). Sanger sequencing of
the probands plus their respective parents confirmed the
segregation of the bi-allelic GFM2 variants with disease
in both families (Fig. 2a, b). All GFM2 variants have been
submitted to ClinVar (https://www.ncbi.nlm.nih.gov/
clinvar/) with the following identifiers: c.569G>A,
SCV000605919; c.636delA, SCV000605920; c.275A>C,
SCV000605921.
Missense residue conservation and in silico predictions
of pathogenicity
Sequence conservation of each missense variant, along with
the surrounding residues, showed that the p.Arg190 residue is
conserved in mammals, but is less so in lower species. The
region flanking the p.(Arg190Gln) change is moderately con-
served (Fig. 2c). In contrast, the homozygous p.(Tyr92Ser)
variant in Patient 2 involves a tyrosine that is conserved from
humans through to yeast and the entire surrounding region is
extremely well conserved (Fig. 2d).
All three GFM2 variants are extremely rare; the
c.564A>G, p.(Arg190Gln) allele, harboured by Patient 1,
i s p r e s e n t i n 5 / 2 7 6 , 0 7 2 a l l e l e s o n g n omAD
(MAF = 0.00002), while the c.275A>C, p.(Tyr92Ser) var-
iant present in Patient 2 in a homozygous state is entirely
novel. In silico tools produced mixed predictions—the
p.(Tyr92Ser) missense variant was classified as likely to
affect protein function according to all four in silico pre-
d i c t i on too l s . S IFT and aGVFD clas s i f i ed the
p.(Arg190Gln) change in Patient 1 as unlikely to interfere
with protein function while PolyPhen was strongly sup-
portive of a deleterious effect. CADD scores were 35 for
c.564A>G and 28.7 for c.275A>C, predicting that these
variants are in the top 0.01 and 0.1% of deleterious single
nucleotide variants of the reference genome, respectively.
Western blotting studies reveal varying OXPHOS defects
Western blot analysis was performed on the fibroblast ly-
sates from both patients to investigate the effect of the
GFM2 variants on the steady-state levels of individual
OXPHOS complex subunits. There was no apparent effect
on the abundance of OXPHOS components in fibroblast
cells from Patient 1 (Fig. 3a), consistent with the mild
biochemical defects reported on direct enzyme assay.
However, a clear decrease in steady-state levels of
NDUFB8 (complex I), CYTB and CORE2 (complex III)
and COXI and COXII (complex IV) was observed in the
fibroblasts of Patient 2 compared to controls (Fig. 3a). In
contrast to fibroblasts, skeletal muscle lysates from Patient
1 exhibited a marked decrease in steady-state levels of
complex IV components, COXI and COXII (Fig. 3b). No
skeletal muscle was available for Patient 2.
Investigation into the steady-state level of mtEFG2 was
only possible following Western blot analysis of a skeletal
muscle sample from Patient 1; fibroblast protein lysates re-
peatedly failed to produce a clear signal due to non-
specificity of the commercial antibody in this tissue. The level
of mtEFG2 protein in skeletal muscle from Patient 1 was
approximately 52% of controls when quantified using Image
Lab™ Software (Fig. 3b).
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Fig. 3 Western blot studies and a [35S] translational assay give insight
into molecular effect of GFM2 variants. a Fibroblast Western blot panel,
with SDHA as a loading control. The panel demonstrates decreased
steady-state levels of NDUFB8 (complex I), CORE 2 and CYT B
(complex III) and COX I and COX II (complex IV) in the fibroblasts of
Patient 2, but unchanged levels in the fibroblasts of Patient 1. b Skeletal
muscle Western blot panel for Patient 1, with SDHA as a loading control.
A complex IV deficiency is apparent, with decreased steady-state levels
of COX I and COX II. Steady-state levels of other OXPHOS subunits
remain unchanged. Levels of mtEFG2 protein are ~ 50% of controls. c
[35S] methionine/cysteine incorporation in growing fibroblasts as a
measure of de novo mitochondrial protein synthesis showed no
difference between either Patient 1 or Patient 2 and the controls using
Coomassie stain as loading control (bottom panel)
Fig. 2 Segregation studies and
missense residue conservation. a
Familial pedigree and sequence
data for Patient 1 and parents
demonstrating recessive
inheritance of compound
heterozygous c.569G>A,
p.(Arg190Gln) and c.636delA,
p.(Glu213Argfs*3) GFM2
variants. b Familial pedigree and
sequence data for Patient 2 and
parents demonstrating recessive
inheritance of a homozygous
c.275A>C, p.(Tyr92Ser) GFM2
variant. Multiple sequence
alignment of GFM2 reveals
moderate evolutionary
conservation of the p.Arg190
residue (c) and the p.Tyr92
residue is invariant (d) (both
residues shown by an asterisk)
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[35S] translation assay
To assess whether the GFM2 variants present in Patient 1 and
Patient 2 cause any impairment of de novo mitochondrial
protein synthesis in growing fibroblast cells, a [35S] metabolic
labelling assay was performed. In the case of both Patient 1
and Patient 2, there does not appear to be any effect on the
incorporation of [35S] methionine/cysteine into newly synthe-
sised mitochondrial DNA-encoded proteins (Fig. 3c).
Discussion
Through the application of whole exome sequencing, we have
identified previously unpublished recessive GFM2 variants in
two unrelated patients with clinical features of mitochondrial
disease and biochemical evidence of respiratory chain dysfunc-
tion. Western blot analysis of patient fibroblasts showed differ-
ential effects at the protein level for each of these patients.
While Patient 2 shows decreased steady-state levels of
mitochondrial-encoded OXPHOS subunits NDUFB8 (of com-
plex I), COXI/COXII (of complex IV) and CYTB/CORE2 (of
complex III), indicating a combined OXPHOS deficiency,
steady-state OXPHOS protein levels were relatively unchanged
in Patient 1 when compared to controls (Fig. 3a).
The gene GFM2, located at 5q13.3, encodes the protein
mtEFG2 which has an essential role following the termination
of mitochondrial translation as GTP hydrolysis is necessary
for the recycling of the mitoribosome [17]. To date, GFM2
variants have been identified in four patients (two sets of sib-
lings), with phenotypes described as microcephaly, simplified
gyral pattern and insulin-dependent diabetes in the first report
and Leigh syndrome complicated by arthrogryposis multiplex
congenita in the most recent family [20, 21]. While Leigh
syndrome is a familiar mitochondrial phenotype, there are
clinical aspects to these four cases that are rather atypical for
mitochondrial disease, simplified gyral pattern and
arthrogryposis multiplex. In contrast, the two cases reported
here have a consistent clinical phenotype that is entirely com-
patible with mitochondrial disease and includes ‘red flag’ clin-
ical features such as neurodevelopmental regression.
The steady-state levels of COXI and COXII in the skeletal
muscle of Patient 1 were decreased (Fig. 3b), demonstrating a
complex IV deficiency. These results are in accordance with the
original diagnostic assessment of individual respiratory chain en-
zyme activities in Patient 1, which detected a complex IVactivity
of around 40% of controls. The residual levels of mtEFG2 in
skeletal muscle from Patient 1 were approximately 50% of the
two controls (Fig. 3b). The c.636delA p.(Glu213Argfs*3)GFM2
mutation in Patient 1 causes a frame shift and a premature stop
codon and is, therefore, likely to encode a non-functional truncat-
ed version of mtEFG2 that is likely to undergo nonsense-
mediated mRNA decay. The 50% residual level of steady-state
mtEFG2 seen in the skeletal muscle of Patient 1 can be explained
by the p.(Arg190Gln) variant occurring in a region of the gene
with only moderate sequence conservation. This is supported by
the in silico pathogenicity predictions suggesting the missense
change would not have major impacts on protein stability, con-
sistent with the loss of only 48% normal mtEFG2 levels.
Steady-state OXPHOS subunit deficiency in Patient 1 is
observable in skeletal muscle, but not fibroblasts, indicating
tissue-specific differences. The deficiency of complex IV ac-
tivity was most severe in the muscle (Fig. 1k) and less so in
fibroblasts (Fig. 1l). This tissue-specific discrepancy in se-
verity of OXPHOS defect is not uncommon in defects of
mitochondrial translation and can arise due to the differences
in ATP reliance in either tissue or differential levels of gene
expression in the two tissue types. A number of deficiencies
due to mt-aaRS mutations, such as YARS2 encoding the mito-
chondrial tyrosyl-tRNA synthetase, show a much clearer
OXPHOS defect in myoblasts than fibroblasts. In the case of
pathogenic YARS2 variants, a marked decrease in steady-state
levels of NDUFB8 was observed only in myoblasts [26].
Muscle relies much more heavily on the generation of ATP
through oxidative phosphorylation, and so variants in mito-
chondrial disease genes can on occasion present a much clear-
er effect at the steady-state protein level [27].
The clear difference in severity of OXPHOS defect between
Patient 1 and Patient 2, visible upon Western blotting, can be
explained by considering both the level of sequence conservation
at the missense variant sites and in silico predictions of pathoge-
nicity. There is consensus across two out of four prediction
programmes (SIFT and aGVGD) that the p.(Arg190Gln) mis-
sense variant present in Patient 1 has a milder consequence com-
pared to the p.(Tyr92Ser) GFM2 variant of Patient 2. Despite
Patient 1 having degradation of mtEFG2 from the allele contain-
ing the p.(Glu213Argfs*3) frameshift mutation, if the
p.(Arg190Gln) amino acid change is less damaging and the re-
maining mtEFG2 protein retains some function, then it might be
expected that the OXPHOS phenotype is less severe.
Despite mtEFG2 playing an important role in the termina-
tion step of mitochondrial translation, our [35S] translational
assay showed no marked decrease in [35S] methionine/
cysteine incorporation in growing fibroblasts as a measure of
de novo mitochondrial protein synthesis, which may have
been expected for Patient 1, due to a lack of clear phenotype
in fibroblast cells. A possible explanation for the signal for
Patient 2 being similar to controls can be found when the stage
of translation at which mtEFG2 exerts its function is consid-
ered. In the majority of cases, mitoribosome recycling occurs
upon completion of synthesis of a nascent peptide [28]. If
mtEFG2 is dysfunctional, it will not prevent the incorporation
of amino acids throughout the synthesis of a peptide, but will
prevent the proper release of this product. Therefore, the sig-
nal coming from incorporated methionine/cysteine will not
differ between control and patient cells.
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In summary, we present two patients with developmental de-
lay, dystonia, dysarthria and neuroimaging abnormalities in the
putamen and caudate nuclei, along with subcortical white matter
involvement who harbour previously unreportedGFM2 variants,
identified through the application of WES. The histochemical,
biochemical and genetic investigations, together with the func-
tional data presented in this report, form compelling evidence
that the GFM2 variants identified through WES are pathogenic
and causative of mitochondrial disease in both patients.
Funding information This work is funded by theWellcome Centre for
Mitochondrial Research (203105/Z/16/Z), the Medical Research Council
(MRC) Centre for Translational Research in Neuromuscular Disease,
Mitochondrial Disease Patient Cohort (UK) (G0800674), the Lily
Foundation, the UK NHS Highly Specialised Service for Rare
Mitochondrial Disorders of Adults and Children and the Department of
Health via the NIHR comprehensive Biomedical Research Centre award
to Guy’s and St. Thomas’ NHS Foundation Trust in partnership with the
King’s College London. CLA was supported by an NIHR/CSO
Healthcare Science Research Fellowship from the National Institute for
Health Research (NIHR-HCS-D12-03-04). TBH was supported by the
German Federal Ministry of Education and Research (BMBF) within the
framework of the e:Med research and funding concept (grant no. FKZ
01ZX1405C). This study was also supported by the German
Bundesministerium für Bildung und Forschung (BMBF) and Horizon
2020 through E-Rare project GENOMIT (01GM1603, 01GM1207 to
H.P.) and the EU Horizon 2020 Collaborative Research Project
SOUND (633974 to H.P.).
Compliance with ethical standards All studies were completed ac-
cording to local Ethical Approval of the Institutional Review Boards of
Newcastle University (the National Research Ethics Service Committee
North East—Newcastle & North Tyneside 1) and of the Technische
Universität München. In agreement with the Declaration of Helsinki, all
individuals or their guardians provided written informed consent before
undergoing evaluation and genetic testing.
Conflict of interest The authors declare that there is no conflict of
interest.
Open Access This article is distributed under the terms of the Creative
Commons At t r ibut ion 4 .0 In te rna t ional License (h t tp : / /
creativecommons.org/licenses/by/4.0/), which permits unrestricted use,
distribution, and reproduction in any medium, provided you give appro-
priate credit to the original author(s) and the source, provide a link to the
Creative Commons license, and indicate if changes were made.
References
1. Anderson S, Bankier AT, Barrell BG et al (1981) Sequence and or-
ganization of the human mitochondrial genome. Nature 290:457–465
2. Wallace DC (1989) Mitochondrial DNA mutations and neuromus-
cular disease. Trends Genet 5:9–13
3. Taylor RW, Pyle A, Griffin H et al (2014) Use of whole-exome
sequencing to determine the genetic basis of multiple mitochondrial
respiratory chain complex deficiencies. JAMA 312:68–77. https://
doi.org/10.1001/jama.2014.7184
4. SisslerM,González-Serrano LE,Westhof E (2017) Recent advances in
mitochondrial aminoacyl-tRNA synthetases and disease. Trends Mol
Med 23:693–708. https://doi.org/10.1016/j.molmed.2017.06.002
5. Pearce S, Nezich CL, Spinazzola A (2013) Mitochondrial diseases:
translation matters. Mol Cell Neurosci 55:1–12. https://doi.org/10.
1016/j.mcn.2012.08.013
6. Alston CL, Rocha MC, Lax NZ et al (2017) The genetics and
pathology of mitochondrial disease. J Pathol 241:236–250.
https://doi.org/10.1002/path.4809
7. Andersson SG, Zomorodipour A, Andersson JO et al (1998) The
genome sequence of Rickettsia prowazekii and the origin of mito-
chondria. Nature 396:133–140. https://doi.org/10.1038/24094
8. O'Brien TW (1971) The general occurrence of 55 S ribosomes in
mammalian liver mitochondria. J Biol Chem 246:3409–3417
9. Kılıç M, Oğuz K-K, Kılıç E et al (2017) A patient with mitochon-
drial disorder due to a novel mutation inMRPS22.Metab Brain Dis
32:1389–1393. https://doi.org/10.1007/s11011-017-0074-5
10. Miller C, Saada A, Shaul N et al (2004) Defective mitochondrial
translation caused by a ribosomal protein (MRPS16) mutation. Ann
Neurol 56:734–738. https://doi.org/10.1002/ana.20282
11. Galmiche L, Serre V, Beinat M et al (2011) Exome sequencing
identifies MRPL3 mutation in mitochondrial cardiomyopathy.
Hum Mutat 32:1225–1231. https://doi.org/10.1002/humu.21562
12. Soiferman D, Ayalon O, Weissman S, Saada A (2014) The effect of
small molecules on nuclear-encoded translation diseases. Biochimie
100:184–191. https://doi.org/10.1016/j.biochi.2013.08.024
13. Diodato D, Ghezzi D, Tiranti V (2014) The mitochondrial
aminoacyl tRNA synthetases: genes and syndromes. Int J Cell
Biol 2014:787956–787911. https://doi.org/10.1155/2014/787956
14. Musante L, Püttmann L, Kahrizi K et al (2017) Mutations of the
aminoacyl-tRNA-synthetases SARS and WARS2 are implicated in
the etiology of autosomal recessive intellectual disability. Hum
Mutat 38:621–636. https://doi.org/10.1002/humu.23205
15. Hammarsund M, Wilson W, Corcoran M et al (2001) Identification
and characterization of two novel human mitochondrial elongation
factor genes, hEFG2 and hEFG1, phylogenetically conserved
through evolution. Hum Genet 109:542–550. https://doi.org/10.
1007/s00439-001-0610-5
16. Zhang D, Yan K, Zhang Yet al (2015) New insights into the enzy-
matic role of EF-G in ribosome recycling. Nucleic Acids Res 43:
10525–10533. https://doi.org/10.1093/nar/gkv995
17. Tsuboi M, Morita H, Nozaki Yet al (2009) EF-G2mt is an exclusive
recycling factor in mammalian mitochondrial protein synthesis. Mol
Cell 35:502–510. https://doi.org/10.1016/j.molcel.2009.06.028
18. Brito S, Thompson K, Campistol J et al (2015) Corrigendum: long-
term survival in a child with severe encephalopathy, multiple respi-
ratory chain deficiency and GFM1 mutations. Front Genet 6:254.
https://doi.org/10.3389/fgene.2015.00254
19. Simon MT, Ng BG, Friederich MW et al (2017) Activation of a
cryptic splice site in the mitochondrial elongation factor GFM1
causes combined OXPHOS deficiency. Mitochondrion 34:84–90.
https://doi.org/10.1016/j.mito.2017.02.004
20. Fukumura S, Ohba C, Watanabe T et al (2015) Compound hetero-
zygous GFM2 mutations with Leigh syndrome complicated by
arthrogryposis multiplex congenita. J Hum Genet 60:509–513.
https://doi.org/10.1038/jhg.2015.57
21. Dixon-Salazar TJ, Silhavy JL, UdpaN et al (2012) Exome sequencing
can improve diagnosis and alter patient management. Sci Transl Med
4:138ra78–138ra78. https://doi.org/10.1126/scitranslmed.3003544
22. Kirby DM, Thorburn DR, Turnbull DM, Taylor RW (2007)
Biochemical assays of respiratory chain complex activity.
Methods Cell Biol 80:93–119. https://doi.org/10.1016/S0091-
679X(06)80004-X
23. Thompson K, Majd H, Dallabona C et al (2016) Recurrent de novo
dominant mutations in SLC25A4 cause severe early-onset mitochon-
drial disease and loss of mitochondrial DNA copy number. Am J
Hum Genet 99:1405. https://doi.org/10.1016/j.ajhg.2016.11.001
Neurogenetics
24. Kremer LS, Bader DM, Mertes C et al (2017) Genetic diagnosis of
Mendelian disorders via RNA sequencing. Nat Commun 8:15824.
https://doi.org/10.1038/ncomms15824
25. Chomyn A (1996) In vivo labeling and analysis of human mito-
chondrial translation products. Meth Enzymol 264:197–211
26. Sommerville EW, Ng YS, Alston CL et al (2017) Clinical features,
molecular heterogeneity, and prognostic implications in YARS2-
related mitochondrial myopathy. JAMA Neurol. https://doi.org/
10.1001/jamaneurol.2016.4357
27. Scarpelli M, Todeschini A, Volonghi I et al (2017) Mitochondrial
diseases: advances and issues. Appl Clin Genet 10:21–26. https://
doi.org/10.2147/TACG.S94267
28. Chrzanowska-Lightowlers ZMA, Pajak A, Lightowlers RN (2011)
Termination of protein synthesis in mammalian mitochondria. J
Biol Chem 286:34479–34485. https://doi.org/10.1074/jbc.R111.
290585
Neurogenetics
